Get all premium features to the best stock analysis tool

Water Tower Research Publishes Initiation of Coverage Report on PharmAla Biotech Holdings, Inc., "Monetizing Regulatory Advantage Through IP and Data"

August 27, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on PharmAla Biotech Holdings, Inc. (CSE:MDMA/OTC:MDXXF) titled, “Monetizing Regulatory Advantage Through IP and Data”. The report can be accessed here. PharmAla Biotech Holdings, Inc. (CSE: MDMA/OTCQB: MDXXF) is a Toronto-based biotech focused on developing, manufacturing, and commercializing MDMA and novel MDXX compounds for mental health and neurological disorders. Founded in 2020 by CEO Nick Kadysh, the company operates under a Health Canada Controlled Drugs and Substances Dealer's License and has built an integrated cGMP MDMA supply chain spanning API manufacturing and drug product formulation.

PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner

U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel the proposed licensing of APA-01 to Restora Neurosciences, and will evaluate in-house and co-development pathways Canaccord Genuity LLC has been engaged as exclusive financial advisor and placement agent TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates. 1.  U.S. Patent Granted for Novel Enantioselective Manufacturing Processes PharmAla has been granted United States Patent No.